Processing...
Clinical Trials for Head And Neck Cancer
Search
Search
There are 211 active trials for advanced/metastatic head and neck cancer.
Click on a trial to see more information.
211 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with measurable advanced bladder, lung, head and neck, esophageal, or pancreatic cancer and ECOG 0–1 receive intravenous PF-08046876, an antibody–drug conjugate targeting integrin beta-6 that delivers a camptothecin-class topoisomerase I inhibitor. Dose escalation requires progression after standard therapy; dose optimization and expansion cohorts allow up to two prior systemic therapy lines for advanced disease.
ClinicalTrials.gov ID: NCT07090499
TrialFetch AI summary: Adults with measurable advanced solid tumors that have progressed after standard therapy or lack a standard treatment option receive a single intravenous infusion of IDOV-Immune. This engineered oncolytic vaccinia virus is designed to replicate preferentially in tumor cells, destroy them, and stimulate antitumor immunity.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with previously treated, locally advanced unresectable or metastatic FAP-positive solid tumors receive intravenous LY4337713, an investigational lutetium-177 radioligand that targets fibroblast activation protein on cancer-associated fibroblasts to deliver radiation to tumors. Eligible cancers include pancreatic, breast, ovarian, gastric, colorectal, esophageal, and cholangiocarcinoma.
ClinicalTrials.gov ID: NCT07213791
TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors who have exhausted standard treatment options or have no standard therapy receive intravenous TJ101, a bispecific antibody-drug conjugate targeting EGFR and B7-H3, every 21 days. Prior topoisomerase I inhibitor treatment is excluded.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Adults with refractory, locally advanced or metastatic NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, esophageal or gastric/GEJ cancer, or cervical, endometrial, or ovarian cancer (ECOG 0–1) receive NRM-823 alone or with an immune checkpoint inhibitor. NRM-823 is an investigational T-cell engager intended to bring T cells into contact with tumor cells; its tumor-binding target has not been publicly confirmed.
ClinicalTrials.gov ID: NCT07182149
TrialFetch AI summary: Adults with relapsed or refractory, locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation receive once-daily oral PLX-61639 after approved treatment options have been exhausted or deemed unsuitable. PLX-61639 is an investigational degrader that recruits DCAF16 to eliminate SMARCA2, a protein on which SMARCA4-deficient tumors may depend.
ClinicalTrials.gov ID: NCT07284186
TrialFetch AI summary: Adults with progressing relapsed or refractory, locally advanced inoperable or metastatic CRPC, colorectal, lung, head and neck, gynecologic, triple-negative breast, or esophageal squamous cell cancer receive 177Lu-BetaBart in a single-arm dose-escalation and expansion study. This investigational lutetium-177–labeled antibody targets B7-H3 (CD276) to deliver radiation to tumors.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808
TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.
ClinicalTrials.gov ID: NCT07517198